A lipid molecule invisible to the naked eye may hold a key to understanding why prostate cancer patients of different ancestry respond differently to the same treatment. Researchers at Duke University School of Medicine have discovered that ceramides—fatty compounds in cells that regulate everything from how cells divide to how they die—behave differently in Black and white patients with metastatic castration-resistant prostate cancer, potentially explaining their divergent responses to androgen receptor pathway inhibitor drugs.
This finding matters because prostate cancer remains a leading cause of cancer death among men, and racial disparities in outcomes persist even when patients receive the same medications. By identifying a biological mechanism linked to these differences, scientists may be able to develop more personalized approaches that work better for all patients.
The research builds on two earlier clinical trials in which investigators noticed that Black and white patients responded differently to androgen receptor pathway inhibitors—medications designed to decrease or block hormones like testosterone in men whose cancer continues to grow despite castrate levels of the hormone. Rather than attributing these differences purely to socioeconomic or healthcare access factors, the Duke team looked deeper into the molecular level.
The researchers focused specifically on ceramides with different carbon chain lengths: 24-carbon ceramides, which tend to help cancer cells survive, and 16-carbon ceramides, which push cancer cells toward death. The balance between these two types matters significantly. Before treatment began, Black patients had lower total ceramide levels overall, but interestingly, they had higher ratios of the protective 24-carbon ceramides compared to white patients. This pattern flipped during treatment. Once patients started taking the androgen receptor pathway inhibitors, Black patients showed lower protective ceramide ratios while white patients showed higher ones—a reversal that correlated with how well the drugs worked.
When the team analyzed blood samples from trial participants, they also found that certain ceramide types were associated with faster cancer progression and worse survival outcomes, with notable differences between the two groups. This wasn't merely an observation about who got sicker faster; it pointed to a measurable biological mechanism rooted in genetic ancestry that influenced how their bodies processed these crucial lipid molecules.
"The two previous clinical studies we conducted were unique with respect to including equal numbers of Black and white patients and collecting trial participants' blood," said senior author Jennifer A. Freedman, Ph.D., of Duke University School of Medicine. "This created an unprecedented opportunity to explore potential biomarkers that may associate with patient self-reported race and genetic ancestry and treatment outcome."
The findings, published in the journal Cancer in 2026 by Sean A. Piwarski and colleagues, represent a departure from studies that fail to adequately represent diverse populations. By deliberately enrolling equal numbers of Black and white participants and carefully measuring their blood chemistry before and during treatment, the researchers created what Freedman calls an unprecedented window into ancestry-related biology and treatment response.
The path forward is clear: further investigation into how genetic ancestry shapes ceramide metabolism could lead to better prostate cancer outcomes across all populations. Rather than accepting disparities as inevitable, this research suggests they may be preventable through targeted interventions informed by understanding each patient's unique lipid profile and genetic background.